Logo image of RYET

RUANYUN EDAI TECHNOLOGY INC (RYET) Stock Fundamental Analysis

NASDAQ:RYET - Nasdaq - KYG7710T1058 - Common Stock - Currency: USD

1.56  0 (0%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to RYET. RYET was compared to 72 industry peers in the Diversified Consumer Services industry. Both the profitability and financial health of RYET have multiple concerns. RYET has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RYET had negative earnings in the past year.
RYET had a negative operating cash flow in the past year.
RYET Yearly Net Income VS EBIT VS OCF VS FCFRYET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 2M -2M

1.2 Ratios

RYET's Return On Assets of -36.57% is on the low side compared to the rest of the industry. RYET is outperformed by 77.78% of its industry peers.
Industry RankSector Rank
ROA -36.57%
ROE N/A
ROIC N/A
ROA(3y)-19.9%
ROA(5y)N/A
ROE(3y)-301.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RYET Yearly ROA, ROE, ROICRYET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Gross Margin of RYET (35.20%) is worse than 61.11% of its industry peers.
RYET does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RYET Yearly Profit, Operating, Gross MarginsRYET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 20 -20 40

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, RYET has about the same amount of shares outstanding.
The debt/assets ratio for RYET is higher compared to a year ago.
RYET Yearly Shares OutstandingRYET Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
RYET Yearly Total Debt VS Total AssetsRYET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

RYET has an Altman-Z score of 1.39. This is a bad value and indicates that RYET is not financially healthy and even has some risk of bankruptcy.
RYET has a Altman-Z score of 1.39. This is comparable to the rest of the industry: RYET outperforms 58.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.39
ROIC/WACCN/A
WACCN/A
RYET Yearly LT Debt VS Equity VS FCFRYET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 2M -2M

2.3 Liquidity

RYET has a Current Ratio of 0.77. This is a bad value and indicates that RYET is not financially healthy enough and could expect problems in meeting its short term obligations.
RYET has a worse Current ratio (0.77) than 65.28% of its industry peers.
A Quick Ratio of 0.76 indicates that RYET may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.76, RYET is doing worse than 65.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.76
RYET Yearly Current Assets VS Current LiabilitesRYET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

RYET shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.20%.
RYET shows a small growth in Revenue. In the last year, the Revenue has grown by 0.23%.
EPS 1Y (TTM)-70.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.6%
Revenue 1Y (TTM)0.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-34.49%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RYET Yearly Revenue VS EstimatesRYET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RYET reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYET Price Earnings VS Forward Price EarningsRYET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYET Per share dataRYET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RYET does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RUANYUN EDAI TECHNOLOGY INC

NASDAQ:RYET (8/8/2025, 11:57:14 AM)

1.56

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.69%
Ins Owner ChangeN/A
Market Cap0
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.97
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.39
BVpS-0.01
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.2%
FCFM N/A
ROA(3y)-19.9%
ROA(5y)N/A
ROE(3y)-301.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.85
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.03%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.76
Altman-Z 1.39
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.6%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-34.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-129.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.11%
OCF growth 3YN/A
OCF growth 5YN/A